Published in Fam Cancer on June 02, 2009
Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet (2012) 1.53
Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet (2010) 1.28
Users' motivations to purchase direct-to-consumer genome-wide testing: an exploratory study of personal stories. J Community Genet (2011) 1.28
Is there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context. J Community Genet (2011) 1.25
Parents' attitudes toward pediatric genetic testing for common disease risk. Pediatrics (2011) 1.18
An exploration of genetic health professionals' experience with direct-to-consumer genetic testing in their clinical practice. Eur J Hum Genet (2012) 1.17
Direct-to-consumer genetic testing: an assessment of genetic counselors' knowledge and beliefs. Genet Med (2011) 1.16
Growing up in the genomic era: implications of whole-genome sequencing for children, families, and pediatric practice. Annu Rev Genomics Hum Genet (2013) 1.11
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? Eur J Hum Genet (2011) 0.98
Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Society of Human Genetics and European Society of Human Reproduction and Embryology. Eur J Hum Genet (2013) 0.87
Experience, knowledge, and opinions about childhood genetic testing in Batten disease. Mol Genet Metab (2013) 0.87
How Much Control Do Children and Adolescents Have over Genomic Testing, Parental Access to Their Results, and Parental Communication of Those Results to Others? J Law Med Ethics (2015) 0.83
Internet-Based Direct-to-Consumer Genetic Testing: A Systematic Review. J Med Internet Res (2015) 0.81
Communication is the key. : Part 2 : Direct to consumer genetics in our future daily life ? J Cell Commun Signal (2014) 0.80
Health care providers and direct-to-consumer access and advertising of genetic testing in the United States. Genome Med (2011) 0.78
Interest, rationale, and potential clinical applications of genetic testing for mood disorders: a survey of stakeholders. J Affect Disord (2012) 0.76
Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet (1995) 6.82
Public health. A case study of personalized medicine. Science (2008) 3.64
A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet (2008) 3.25
Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA (2002) 2.30
Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet (2006) 2.01
Regulators weigh risks of consumer genetic tests. Nat Biotechnol (2008) 1.84
Genetic testing in asymptomatic minors: Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2009) 1.80
Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests. Am J Med Genet C Semin Med Genet (2006) 1.26
Developmental tasks of childhood and adolescence: implications for genetic testing. Am J Med Genet (1997) 1.17
Risk as moral danger: the social and political functions of risk discourse in public health. Int J Health Serv (1993) 1.10
Direct-to-consumer genome scanning services. Also for children? Nat Rev Genet (2009) 1.00
Whose genes are these anyway?: familial conflicts over access to genetic information. Mich Law Rev (1993) 0.94
Guidelines for genetic testing of healthy children. Paediatr Child Health (2003) 0.93
Is my sick child healthy? Is my healthy child sick?: changing parental experiences of cystic fibrosis in the age of expanded newborn screening. Soc Sci Med (2008) 0.88
Caveat emptor: direct-to-consumer supply and advertising of genetic testing. Clin Invest Med (2004) 0.82
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.93
Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics (2012) 1.48
Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing. Eur J Hum Genet (2017) 1.39
Whole-genome sequencing in newborn screening programs. Sci Transl Med (2014) 1.34
Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod (2011) 1.32
Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.31
Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Eur J Hum Genet (2010) 1.29
Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet (2010) 1.28
Users' motivations to purchase direct-to-consumer genome-wide testing: an exploratory study of personal stories. J Community Genet (2011) 1.28
The expansion of newborn screening: is reproductive benefit an appropriate pursuit? Nat Rev Genet (2009) 1.21
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Storing newborn blood spots: modern controversies. J Law Med Ethics (2004) 1.14
Pediatric research and the return of individual research results. J Law Med Ethics (2011) 1.14
Science and society: children and incompetent adults in genetic research: consent and safeguards. Nat Rev Genet (2002) 1.13
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum. Ann Neurol (2003) 1.05
Cohort profile: the maternal-infant research on environmental chemicals research platform. Paediatr Perinat Epidemiol (2013) 1.03
Direct-to-consumer genome scanning services. Also for children? Nat Rev Genet (2009) 1.00
Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur J Hum Genet (2009) 0.99
Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? Eur J Hum Genet (2011) 0.98
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet Med (2013) 0.91
"I prefer a child with …": designer babies, another controversial patent in the arena of direct-to-consumer genomics. Genet Med (2013) 0.90
A review of the barriers to sharing in biobanking. Biopreserv Biobank (2013) 0.90
Paediatric biobanks: what makes them so unique? J Paediatr Child Health (2011) 0.87
Recruiting terminally ill patients into non-therapeutic oncology studies: views of health professionals. BMC Med Ethics (2012) 0.87
Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care (2008) 0.86
Expectations and values about expanded newborn screening: a public engagement study. Health Expect (2013) 0.86
Physicians and genetic malpractice. Med Law (2002) 0.83
Emerging issues in paediatric health research consent forms in Canada: working towards best practices. BMC Med Ethics (2013) 0.83
Newborn blood spot screening in four countries: stakeholder involvement. J Public Health Policy (2008) 0.82
Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. Eur J Hum Genet (2013) 0.82
Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet (2015) 0.80
Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. OMICS (2011) 0.80
Understanding umbilical cord blood banking: what women need to know before deciding. Womens Health Issues (2007) 0.80
Direct-to-consumer genetic testing: driving choice? Expert Rev Mol Diagn (2010) 0.79
Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab (2012) 0.79
Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider. J Community Genet (2012) 0.79
Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health. Curr Pharmacogenomics Person Med (2011) 0.79
An ethical and legal overview of pharmacogenomics: perspectives and issues. Med Law (2008) 0.78
The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study. J Popul Ther Clin Pharmacol (2011) 0.78
[Severe neuropathy with agenesis of the corpus callosum]. Med Sci (Paris) (2003) 0.77
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited. Front Pharmacol (2013) 0.77
Public concerns regarding the storage and secondary uses of residual newborn bloodspots: an analysis of print media, legal cases, and public engagement activities. J Community Genet (2014) 0.76
Are we asking the right ethics questions on drug shortages? Suggestions for a global and anticipatory ethics framework. Am J Bioeth (2012) 0.75
Ethics, industry and 'animal farm'. Nat Biotechnol (2004) 0.75
Genetic testing: anonymity of sperm donors under threat. Nature (2013) 0.75
Responsible implementation of expanded carrier screening. Eur J Hum Genet (2017) 0.75